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Background: Dendritic cells (DCs) control immunity and play a role in the pathogenesis of chronic obstructive
pulmonary disease (COPD). However, the expression of function-associated surface molecules on circulating DCs in
COPD is unknown.
Methods: Four-colour flow cytometry was used to compare blood DC surface molecules of 54 patients with COPD
(median age: 59 years; median FEV1: 38% predicted, median CAT score: 24) with two age-matched control groups
with normal lung function: 21 current smokers and 21 never-smokers.
Results: Concentrations of plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) and the mDC/pDC ratio did not
differ between the groups. The increased expression of BDCA-1, BDCA-3, CD86 and CCR5 on mDCs in patients with
COPD did not significantly differ from smokers with normal lung function. In contrast, COPD was specifically characterised
by a decreased expression of the anti-inflammatory co-stimulatory molecule PD-L1 on pDCs and an increased expression
of the pro-inflammatory co-stimulatory molecule OX40 ligand (OX40L) on mDCs. These changes were not confined to
patients with elevated systemic inflammation markers (leukocytes, c-reactive protein, interleukin-6, fibrinogen). The ratio
of OX40L to PD-L1 expression (OX40L/PD-L1 ratio), a quantitative measure of imbalanced DC co-stimulation, correlated
with the severity of pulmonary emphysema in patients with COPD.
Conclusion: An imbalance of DC co-stimulation might contribute to the pathogenesis of COPD.
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Chronic obstructive pulmonary disease (COPD) is a
chronic inflammatory disorder characterised by both
local abnormalites (including a specific type of airway
inflammation) and systemic abnormalities (including
typical co-morbidities and various degrees of systemic
inflammation) [1]. An abnormal immune response to
inhaled noxious agents is a central pathogenetic feature of
COPD, leading to lymphoid follicle formation around the
airways and small airway obstruction [1]. Smoking is the
most important risk factor for the development of COPD.
However, less than 30% of all smokers develop COPD [2]
and it is still unclear which specific immunologic features
account for COPD development.
Dendritic cells (DCs), which can be subdivided into
myeloid DCs (mDCs) and plasmacytoid DCs (pDCs),
control pulmonary immune responses. DC accumulation
and activation in the airways has been postulated to be a* Correspondence: marek.lommatzsch@med.uni-rostock.de
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unless otherwise stated.driver of COPD immunopathology [3-9]. Using an estab-
lished method to analyse human bronchoalveolar lavage
fluid DCs [10-13], we have shown that airway mDCs of
asymptomatic smokers show a profound adaptation to
cigarette smoke exposure, including a strong upregula-
tion of antigen-recognition receptors such as CD1a,
BDCA-1 or Langerin and co-stimulatory molecules such
as CD86 [11]. Of note, this upregulation was also found
on airway mDCs of current smokers with COPD, but
not former smokers with COPD, suggesting that these
changes are related to smoke exposure, rather than the
presence of COPD. In addition, this upregulation corre-
lated with less airway obstruction, further supporting the
concept that an upregulation of these markers is not
related to COPD pathogenesis [14]. Thus, the specific
causes of chronic airway inflammation in COPD are still
enigmatic. It has been postulated that enhanced local
concentrations of chemokines contribute to the accumula-
tion of DCs and the subsequent activation of lymphoyctes
[3]. We hypothesised that there may be additional changes
of co-stimulatory molecules on circulating DCs contributingis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of the present study, therefore, to study major co-
stimulatory molecules such as programmed death lig-
and 1 (PD-L1) or OX40 ligand (OX40L) and other
function-associated surface molecules on circulating
DCs of patients with COPD for the first time, and to
compare the findings with control groups of asymp-
tomatic smokers and never-smokers.
Methods
Participants
Controls were recruited using public notices in Rostock
(Germany). Patients with stable COPD were recruited at
the University Hospital of Rostock (Germany). Inclusion
criteria for patients with COPD were as follows: 1. doctor’s
diagnosis of COPD, 2. age between 40 and 85 years, 3.
smoking history of at least 5 pack years, 3. a FEV1/FVC ra-
tio < 70% after inhalation of a short-acting beta-agonist.
Former smokers were defined as subjects who quit
smoking at least 4 weeks before study inclusion. Exclu-
sion criteria for patients with COPD were: 1. presence
of any malignant diseases, 2. any signs of an infection/
exacerbation or any treatment with antibiotics or short-
term corticosteroids within the last 4 weeks prior to
enrollment. Controls were recruited using the following
inclusion criteria: 1. no history of chronic respiratoryTable 1 Characteristics of the participants
Never-smoker (N) Smoker (S
n = 21 n = 21
Age (years) 63 [50–79] 61 [51–75]
Gender (male/female) 12/9 13/8
BMI (kg/m2) 26 [21–32] 29 [18–39]
Waist circumference (cm) 90 [66–125] 101 [72–11
Pack-years (PY) 0 [0–0] 39 [23–69]
Smoking status (NS/CS) 0 / 21 21 / 0
LAMA/LABA/ICS (No. treated) 0/0/0 0/0/0
THEO/ROF/OCS (No. treated) 0/0/0 0/0/0
mMRC 0 [0–1] 0 [0–2]
CAT 4 [0–14] 7 [1–20]
FEV1 (Liters) 3.2 [1.9-5.1] 2.9 [1.8-3.9
FEV1 (% predicted) 112 [84–133] 98 [66–124
FEV1%FVC (%) 81 [73–86] 80 [71–94]
MEF50 (% predicted) 81 [45–148] 75 [29–123
RV (% predicted) 99 [29–145] 107 [64–14
TLC (% predicted) 103 [71–120] 98 [68–127
Parameters are displayed as median values [minimum…maximum]. Abbreviations d
(LABA), Inhaled corticosteroid (ICS), Theophyllin (THEO), Roflumilast (ROF), Oral corti
test (CAT), Inspiratory vital capacity (IVC), Forced expiratory volume in the first one
maximum expiratory flow at 50% of VC (MEF50), residual volume (RV), total lung ca
side of the table show comparisons between the groups: Asymptomatic smokers (S
medication with LAMA, LABA and ICS. **p < 0.05 for differences in medication withdiseases, 2. age between 40 and 85 years, 3. no history of
smoking and no exposure to smoking partners or relatives
at home (never-smoking controls) or a smoking history
of at least 5 pack years and current smoking of at least
15 cigarettes per day (asymptomatic current smokers).
For both control groups, exclusion criteria were as fol-
lows: 1. presence of any malignant or chronic inflamma-
tory diseases, 2. any signs of an infection or treatment
with antibiotics within the last 4 weeks prior to enroll-
ment. The study was approved by the local ethics com-
mittee of the Ärztekammer Mecklenburg-Vorpommern,
Rostock (Germany). All participants gave their written
informed consent.
Study design
All participants were examined between 8 am and
12 pm. Lung function tests and blood sampling were
performed on the same day. In a first step, informed
consent was obtained and a structured history was taken.
Subsequently, body plethysmography was performed and
the diffusion capacity (DLCO) measured (Masterscreen,
Jaeger, Carefusion, Hoechberg, Germany). Then, periph-
eral blood was taken for laboratory analyses (differential
blood counts, fibrinogen, c-reactive protein, Interleukin-6
and 25-OH-Vitamin D) and for the analysis of blood DCs
and T cells.) COPD (C) S vs. N C vs. N C vs. S
n = 54 p-value p-value p-value
59 [40–85] 0.337 0.274 0.859
33/21 0.753 0.753 0.949
25 [15–41] <0.05 0.683 <0.05
5] 91 [64–130] <0.05 0.432 0.102
38 [5–80] <0.001 <0.001 0.262
12 / 42 <0.001 <0.05 <0.001
51/50/31 NA <0.001* <0.001*
12/8/10 NA <0.05** <0.05**
2 [1–4] 0.076 <0.001 <0.001
24 [7–35] 0.050 <0.001 <0.001
] 1.0 [0.5-2.4] 0.113 <0.001 <0.001
] 38 [16–75] <0.01 <0.001 <0.001
49 [28–69] 0.521 <0.001 <0.001
] 12 [5–33] 0.122 <0.001 <0.001
1] 199 [76–347] 0.119 <0.001 <0.001
] 118 [79–164] 0.571 <0.001 <0.001
enote: Long-acting muscarinergic antagonist (LAMA), Long-acting Beta-agonist
costeroid (OCS), modified Medical research council (mMRC), COPD assessment
second (FEV1), ratio of the FEV1 to the forced vital capacity (FEV1/FVC),
pacity (TLC), Non-Smoker (NS), Current Smoker (CS). The columns on the right
), never-smokers (N), patients with COPD (C). *p < 0.001 for the differences in
OCS and Theophyllin.
Table 2 Blood parameters
Never-smoker (N) Smoker (S) COPD (C) S vs. N C vs. N C vs. S
n = 21 n = 21 n = 54 p-value p-value p-value
Systemic inflammation (yes/no) 1/20 9/12 27/27 <0.01 <0.001 0.530
Leukocytes (109/l blood) 6.1 [4.0-9.1] 8.7 [4.4-13.7] 8.4 [4.1-13.9] <0.01 <0.001 0.567
CRP (mg/l blood) 1.0 [1.0-8.2] 3.7 [1.0-14.8] 3.5 [1.0-24.3] <0.001 <0.001 0.552
Fibrinogen (g/l blood) 3.0 [2.4-4.8] 3.6 [2.5-5.4] 4.2 [2.2-6.4] <0.05 <0.001 0.153
Interleukin-6 (pg/ml blood) 2.17 [1.50-5.62] 2.42 [1.50-6.94] 4.19 [1.5-14.4] 0.362 <0.001 <0.01
25-OH-Vitamin-D (nmol/l) 54 [24–112] 62 [27–108] 45 [13–115] 0.443 0.294 0.059
Parameters are displayed as median values [minimum…maximum]. Abbreviations denote: C-reactive protein (CRP). Presence of systemic inflammation was defined
according to the proposal by Agusti and colleagues [15]. The columns on the right side of the table show comparisons between the groups: Asymptomatic
Smokers (S), Never-smokers (N), patients with COPD (C).
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Blood dendritic cells were analysed using freshly col-
lected EDTA blood as described [10-13], using the
antibodies detailed in the Additional file 1: Table S1.
Among blood cells negative/dim for lineage markers
(CD3, CD14, CD16, CD19, CD20, CD56), mDCs were
defined as CD11c+HLA-DR+linneg/dim cells and pDCs
as CD123+HLA-DR+linneg/dim cells (Additional file 1:
Figure S1). Surface molecule expression on DCs was
quantified in histogram plots using isotype control
antibodies to discriminate between specific and non-
specific staining (Additional file 1: Figures S2 and S3).
CD4-positive T cells in peripheral blood were defined as
CD3+CD4+ cells, regulatory T cells (Tregs) were definedTable 3 Dendritic cell concentrations and characteristics
Never-smoker (N) Smoker (S)
n = 21 n = 21
mDC (% of leukocytes) 0.19 [0.09-0.39] 0.14 [0.05-0.27]
mDC (103/ml blood) 12.4 [5.0-26.5] 11.0 [3.5-29.2]
pDC (% of leukocytes) 0.09 [0.04-0.25] 0.08 [0.02-0.19]
pDC (103/ml blood) 5.5 [2.8-15.4] 7.0 [1.7-19.4]
ratio mDC/pDC 1.9 [1.0-4.8] 1.3 [0.7-3.6]
mDC surface markers
BDCA-1 (% positive mDC) 61 [37–87] 67 [36–92]
BDCA-3 (% positive mDC) 41 [14–77] 68 [24–100]
CD54 (MFI) 260 [177–373] 251 [87–355]
CD86 (% positive mDC) 24 [1–70] 56 [6–77]
PD-L1 (% positive mDC) 8 [0–31] 11 [1–66]
CCR5 (% positive mDC) 9 [0–63] 12 [0–75]
OX40L (% positive mDC) 9 [1–91] 12 [0–32]
pDC surface markers
CD54 (MFI) 316 [181–480] 351 [251–715]
PD-L1 (% positive pDC) 35 [4–62] 36 [9–73]
Parameters are displayed as median values [minimum…maximum]. Abbreviations d
Dendritic Cell Antigen (BDCA), Cluster of Differentiation (CD), Chemokine Receptor
the table show comparisons between the groups: Asymptomatic smokers (S), neveras CD3+CD4+CD25++CD127low/neg cells (Additional file 1:
Table S1).
Statistical analysis
Statistical analysis was performed using SPSS Statistics
(SPSS Inc., Chicago, Illinois, USA). The majority of pa-
rameters was not normally distributed. Therefore, param-
eters were expressed as medians (minimum – maximum).
For the comparison of groups, the Mann–Whitney-U test
for unrelated samples was used. Correlation analyses were
performed using Spearman’s correlation coefficient.
Probability values of p < 0.05 were regarded as signifi-
cant. Boxplots display the median (line within the
box), interquartil range (edges of the box) and extremesCOPD (C) S vs. N C vs. N C vs. S
n = 54 p-value p-value p-value
0.15 [0.04-0.30] <0.05 <0.05 0.354
10.9 [3.6-31.2] 0.392 0.654 0.575
0.09 [0.02-0.22] 0.595 0.740 0.749
6.4 [1.5-16.9] 0.227 0.145 0.680
1.7 [0.5-5.2] 0.084 0.141 0.575
72 [34–94] 0.505 <0.05 0.101
61 [20–99] <0.001 <0.001 0.516
262 [160–445] 0.651 0.354 0.097
44 [1–92] <0.05 <0.05 0.953
9 [0–41] 0.529 0.925 0.286
28 [0–91] 0.191 <0.01 0.200
16 [5–72] 0.642 <0.05 <0.01
287 [0–698] 0.406 0.124 <0.05
23 [0–80] 0.678 < 0.05 < 0.01
enote: Plasmacytoid Dendritic Cell (pDC), myeloid Dendritic Cell (mDC), Blood
(CCR), Programmed Death Ligand 1 (PD-L1). The columns on the right side of
-smokers (N), patients with COPD (C).
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Results
Characteristics of the participants
Twenty-one never-smokers, 21 asymptomatic current
smokers and 54 patients with the diagnosis of COPD
were included in the study. Characteristics of the partici-
pants are detailed in Table 1. There were no differences
in age and gender distribution between the groups.
There was no difference in the number of pack years
(PY) between the group of asymptomatic smokers and
the group of patients with COPD. Smokers displayed a
higher body mass index (BMI) than never-smokers and
patients with COPD. Patients with COPD displayed sig-
nificantly worse lung function parameters, as compared
to both control groups, with a median FEV1 of 1,0 liters
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Figure 1 Percentages of dendritic cells in peripheral blood. Upper pan
blood leukocytes of 21 never-smokers (Never-smoker), 21 smokers with no
Lower panel: percentages of plasmacytoid DCs (C) and myeloid DCs (D) in
systemic inflammation (no systemic inflammation) and those 27 COPD pat
(systemic inflammation).stage II, 26 patients in spirometric GOLD stage III und
14 patients in spirometric GOLD stage IV. The median
CAT (COPD Assessment Test) score in the COPD group
was 24 (Table 1). One patient was treated with a long-
acting beta-agonist (LABA) monotherapy, 3 patients with
a long-acting muscarinergic antagonist (LAMA) mono-
therapy, 18 patients with a LABA/LAMA combination
therapy, one with a LABA/ICS combination therapy and
30 patients with a LABA/LAMA/ICS triple therapy. Ten
patients (18.5%) were treated with oral corticosteroids
(OCS) and 31 patients (57.4%) with ICS (Table 1).
Markers of systemic inflammation
Blood concentrations of leukocytes, C-reactive protein
(CRP) and fibrinogen were elevated compared to never-
smoking controls, but did not significantly differ be-
tween asymptomatic smokers and patients with COPD
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of neutrophils, eosinophils and lymphocytes among blood
leukocytes between asymptomatic smokers and patients
with COPD (data not shown). In contrast, blood concen-
trations of Interleukin-6 (IL-6) were significantly higher in
patients with COPD, as compared with asymptomatic
smokers and never-smokers (Table 2 and Additional file 1:
Figure S4). Twenty-seven patients with COPD (50%), 9
asymptomatic smokers (43%) and 1 never-smoker (5%)
displayed a systemic inflammation according to the
definition proposed by Agusti and colleagues [15] (at
least two elevated parameters: leukocytes > 8.6 106/ml,
c-reactive protein > 8.7 mg/l, fibrinogen > 5.18 g/l,
Interleukin-6 > 2.6 pg/ml) (Table 2). Blood IL-6 con-
centrations (but not other markers of systemic inflam-
mation) correlated with lung function parameters
(FEV1 % predicted: r = −0.33, p = 0.015; IVC % predicted:
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Figure 2 Concentrations of dendritic cells in peripheral blood. Upper
peripheral blood of 21 never-smokers (Never-smoker), 21 smokers with n
Lower panel: concentrations of plasmacytoid DCs (C) and myeloid DCs (D
systemic inflammation (no systemic inflammation) and those 27 COPD pa
(systemic inflammation).the 6 minute walk test (6-MWT) distance (r = −0.51,
p = 0.001), the CAT score (r = 0.34, p = 0.012) and the
mMRC score (r = 0.41, p = 0.002) in patients with
COPD (Additional file 1: Figure S5). There was no
significant difference in the total concentration of
Tregs and in the percentage of Tregs among CD4-
positive T-cells in peripheral blood between the 3 groups
(Additional file 1: Figure S6).
Percentages and concentrations of DCs in blood
Although the percentages of mDCs in blood were sigi-
ficantly higher in never-smokers than in smokers and
patients with COPD, there were no differences in total
mDC concentrations between the groups. Percentages
and concentrations of pDCs did not differ between the
groups (Table 3 and Figures 1 and 2). The ratio of mDCs
to pDCs in peripheral blood did not differ between the
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current smokers with COPD (n = 12) (data not shown).
Percentages and concentrations of blood mDC did not
differ between patients with systemic inflammation (n = 27)
and patients without systemic inflammation (n = 27)
(Figures 1 and 2). Although the percentage of pDCs was
significantly lower in patients with systemic inflammation
(n = 27), as compared with patients without systemic in-
flammation (n = 27), there was no difference in pDC con-
centrations between these two groups (Figures 1 and 2).
Surface molecule expression on blood DCs
Patients with COPD displayed a significantly increased
expression of BDCA-1 (Figure 3A), BDCA-3 (Figure 3B),
CD86 (Figure 3C) and CCR5 (Figure 3D) on mDCs, as
compared with never-smoking controls. However, the
expression of these markers did not differ between
asymptomatic smokers and patients with COPD (Table 3).

























Never-Smoker Smoker COPD 
p < 0.05 
p < 0.05 
p < 0.05 
A 
C 
Never-Smoker Smoker COPD 
Figure 3 Surface molecule expression on blood mDCs. Boxplots sho
(B), CD86 (C), CCR5 (D) on blood mDCs of 21 never-smokers (Never-Smo
54 patients with COPD (COPD).PD-L1 on mDCs between the groups (Table 3). The ex-
pression of OX40-ligand (OX40L) on mDCs was signifi-
cantly higher in patients with COPD than in both control
groups (Table 3 and Figure 4A). In contrast, the expres-
sion of PD-L1 on pDCs was significantly lower in pa-
tients with COPD, as compared with both control
groups (Table 3 and Figure 4B). Consequently, the ratio
of OX40L expression on mDCs to PD-L1 expression on
pDCs (OX40L/PD-L1 ratio) was significantly increased
in patients with COPD, as compared with both control
groups (Figure 5A). There was no significant correlation
between blood Tregs (total concentrations and percent-
ages among CD4-positive T-cells) and the OX40L ex-
pression on mDCs, PD-L1 expression on pDCs and the
OX40L/PD-L1 ratio (data not shown). CD54 expression
on pDCs was significantly lower in patients with COPD
than in asymptomatic smokers, but did not differ be-
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No systemic inflammation Systemic inflammation
Figure 4 Expression of PD-L1 and OX40L on blood DCs. Upper panel: expression (% positive blood DCs) of OX40L on blood mDCs (A) and
PD-L1 on blood pDCs (B) of 21 never-smokers (Never-Smoker), 21 current smokers with normal lung function (Smoker) and 54 patients with
COPD (COPD). Lowe panel: expression (% positive blood DCs) of OX40L on blood mDCs (C) and PD-L1 on blood pDCs (D) in those 27 COPD
patients with less than 2 elevated markers of systemic inflammation (no systemic inflammation) and those 27 COPD patients with at least 2
elevated markers of systemic inflammation (systemic inflammation).
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There was no significant association of the mDC OX40L
or pDC PD-L1 expression with anthropometric parame-
ters, pulmonary function, the 6-MWT distance or the
CAT score in patients with COPD (data not shown).
There was no significant association of the OX40L/PD-
L1 ratio with anthropometric parameters, the 6-MWT
distance or the CAT score in patients with COPD (data
not shown). In contrast, the OX40L/PD-L1 ratio correlated
significantly with parameters of pulmonary emphysema
such as the diffusion capacity (DLCO), the residual volume
(RV) or the total lung capacity (TLC) (Figure 5B-D).
Subgroup analyses
The expression of DC surface molecules did not signifi-
cantly differ between current smokers (n = 12) and former
smokers with COPD (n = 42)(data not shown). The ex-
pression of OX40L on mDCs, the expression of PD-L1 onpDCs and the OX40L/PD-L1 ratio did not significantly
differ between patients with spirometric GOLD stages II
(n = 14), III (n = 26) and IV (n = 14) (Figure 6A-C) and be-
tween current smokers (n = 12) and former smokers with
COPD (n = 42)(Figure 6D-F), although the highest median
OX40L/PD-L1 ratios were found in the subgroup of
current smokers with COPD and in the subgroup of pa-
tients with spirometric GOLD stage IV (Figure 6C, F).
Despite an increase in CCR5 expression (p = 0.044) in
OCS treated patients, there were no differences in DC sur-
face molecules expression between patients treated with
OCS (n = 10) and patients not treated with OCS (n = 44).
No differences in surface molecule expression was ob-
served between patients treated with ICS (n = 31) and pa-
tients not treated with ICS (n = 23)(data not shown).
Presence of systemic inflammation did not have an impact
on the expression of the examined DC surface molecules.
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Figure 5 OX40L / PD-L1 ratio and its association with emphysema. Graph A shows the ratio of OX40L expression on mDCs to PD-L1
expression on pDCs (OX40L/PD-L1 ratio) of 21 never-smokers (Never-Smoker), 21 current smokers with normal lung function (Smoker) and 54
patients with COPD (COPD). The other graphs show the correlation between the OX40L/PD-L1 ratio and the diffusion capacity (DLCO) (B), the
residual volume (RV) (C) and the total lung capacity (TLC) (D) of the 54 patients with COPD. The Spearman’s correlation coefficient (r) and the
p-value (p) is given for each correlation.
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tween patients with systemic inflammation (n = 27) and
patients without systemic inflammation (n = 27) (Figure 4C
and D).
Discussion
This is the first report showing an imbalance of DC
co-stimulation in COPD. We demonstrate a specific
increase in the pro-inflammatory co-stimulatory mol-
ecule OX40L on blood mDCs and a specific decrease
in the anti-inflammatory co-stimulatory molecule PD-
L1 on blood pDCs in COPD. In addition, we show that
the OX40L/PD-L1 ratio, as a quantitative measure of
this imbalance, correlates with the severity of pulmon-
ary emphysema. Thus, the observed imbalance of DC
co-stimulation might contribute to the pathogenesis of
COPD.Programmed death ligand 1 (PD-L1, also known as
B7-H1), a member of the family of co-stimulatory B7 re-
ceptors, is expressed on DCs and binds to the CD28
family member PD-1 on T-cells [16]. The interaction of
PD-L1 with PD-1 has anti-inflammatory effects by indu-
cing regulatory T cells (Tregs) and suppressing self- and
allo-reactive T cells [17-19], and plays a central role in
the prevention of autoimmune and chronic inflamma-
tory diseases [16]. PD-L1 is an important component of
the anti-inflammatory functions of pDCs [20]. T cells
upregulate PD-1 on the surface following activation [16].
The elevated expression of PD-1 on circulating CD4+ T
cells in COPD [21] might, therefore, be related to a
chronic T cell ativation in this condition. We show a de-
creased expression of the corresponding ligand (PD-L1)
on pDCs in COPD and speculate that this defective















































































GOLD II GOLD III GOLD IV GOLD II GOLD III GOLD IV GOLD II GOLD III GOLD IV 
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D E F 
Former smoker Current smoker Former smoker Current smoker Former smoker Current smoker 
Figure 6 Subgroup analyses. The expression of OX40L on mDCs, the expression of PD-L1 on pDCs and the OX40L/PD-L1 ratio is shown for the
subgroups of patients with spirometric GOLD stages II (n = 14), III (n = 26) and IV (n = 14) (Panel A-C) and for the subgroups of current smokers
with COPD (n = 12) and former smokers with COPD (n = 42) (Panel D-F). There were no significant differences between the subgroups for
each parameter.
Stoll et al. Respiratory Research  (2015) 16:19 Page 9 of 11pDCs to control inflammation, contributing to chronic
inflammation in COPD. Therefore, further studies are
needed to investigate the role of the PD-L1/PD-1 axis
in COPD pathogenesis.
In contrast to PD-L1, we found an increased expression
of OX40L on circulating mDCs in COPD. The expression
of OX40L, a costimulatory molecule of DCs binding to
the OX40 receptor on T cells, has been shown to be regu-
lated by thymic stromal lymphopoietin (TSLP) which is
primarily derived from bronchial epithelial cells [22]. A
TSLP-induced stimulation of the OX40L/OX40 axis has
pro-inflammatory effects [22]. As a key driver of Th2
immune responses, TSLP has been postulated to play a
major pathogenetic role in asthma [23]. However, an in-
creased expression of TSLP has also been found in COPD
[22,24]. In addition, there is an increased OX40 expression
on circulating T cells (especially CD8+ T cells) in patients
with COPD [25]. Thus, the increased OX40L expression
on circulating mDCs observed in the current study sug-
gests an upregulation of the OX40L/OX40 axis in COPD.
There is an ongoing discussion on possible therapeutic
implications of increased TSLP and Th2 cytokine pro-
duction in COPD [26,27]. Our results suggest that the
OX40L/OX40 axis might be involved in COPD patho-
genesis and could represent a potential new target for
COPD treatment.
In order to quantify the extent of the imbalanced ex-
pression of co-stimulatory molecules on DCs, we calcu-
lated the ratio of OX40L expression on mDCs to PD-L1expression on pDCs (“OX40L/PD-L1 ratio”). This ratio
was significantly increased in patients with COPD (as
compared with both control groups) and correlated with
the severity of pulmonary emphysema. These data sug-
gest that the observed imbalance of DC co-stimulation
might contribute to the complex immunopathogenesis
of emphysema in COPD [28]. In contrast, we did not find
a significant correlation between the OX40L/PD-L1 ratio
and circulating Tregs (CD3+CD4+CD25++CD127low/neg
cells) in patients with COPD. This finding does not neces-
sarily rule out an association between the imbalanced DC
co-stimulation and altered Treg functionality in COPD as
there are several methods to measure Tregs and their vari-
ous subclasses and functions [21,29]. Therefore, further
clinical and laboratory studies are needed to better under-
stand the relationship between altered DC phenotypes
and T cell functions in COPD.
The chemokine receptor CCR5 has been implicated in
the pathogenesis of COPD [30]. CCR5 deficiency results
in a marked reduction in airway inflammation and a re-
duced formation of peribronchial lymphoid follicles in
animal models of COPD [31]. Here, we demonstrate that
CCR5 is upregulated on blood mDCs in patients with
COPD. CCR5 ligands such as CCL4 (MIP-1beta) and
CCL5 (RANTES) are known to be increased in the air-
way wall of patients with COPD [32,33]. We hypothesise
that an increased expression of CCR5 on blood mDCs
and increased concentrations of CCR5 ligands in the air-
way wall lead to an selective accumulation of these
Stoll et al. Respiratory Research  (2015) 16:19 Page 10 of 11mDCs in the airway wall. This accumulation has two
possible implications. First, the local increase in mDCs
could contribute to lymph follicle formation and small
airway inflammation in COPD [1]. Second, the retention
of CCR5-positive mDCs in the airway wall could result
in a decrease of CCR5-positive mDCs in the airway lumen.
Because CCR5 plays an important role in the uptake of mi-
crobial antigens, this decrease may contribute to an altered
response to microbial antigens in COPD airways [14].
There is substantial evidence suggesting increased DC
concentrations in the lung parenchyma of patients with
COPD [3-6], however, there are conflicting reports on
blood DC concentrations in patients with COPD [21,34].
Galgani and colleagues postulated a decrease in blood
pDCs (and a resulting increase in the mDC/pDC ratio)
[34], whereas Kalathil and colleagues [21] and our study
did not find differences in blood pDC concentrations be-
tween patients with COPD and controls. One possible ex-
planation for the discrepancy between the studies might be
differences in the medication of the patients, the severity of
the disease and the presence of different comorbidities.
Therefore, further studies are needed to better understand
the regulation of pDC concentrations in COPD.
It has been postulated that mDCs can be subdivided
into BDCA-1-positive mDCs (“mDC1”) and BDCA-3
positive mDCs (“mDC2”) [35,36], based on a study with
blood mDCs from healthy volunteers [37]. However,
BDCA-3 can be upregulated on BDCA-1 positive mDCs
[37]. In human airways, both BDCA-1 and BDCA-3 are
expressed on > 50% of all mDCs, suggesting an overlap
in the expression of both markers [10,11,14]. In the
current study, both markers were upregulated on blood
mDCs (expression on > 60% of mDCs) in asymptomatic
smokers and in patients with COPD suggesting that the
clear distinction between these two blood mDC popula-
tions is lost in these conditions. The functional conse-
quences of these findings are currently unclear and need
further investigation.
Conclusion
This study shows, for the first time, that an imbalanced
expression of co-stimulatory molecules on circulating
DCs is associated with the severity of pulmonary emphy-
sema in COPD. These findings will help to understand
the immunopathogenesis of COPD.Additional file
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